Navigation Links
Astex, CRT and the Institute of Cancer Research announce epigenetic drug discovery collaboration
Date:9/7/2012

Astex Pharmaceuticals, Inc (NASDAQ: ASTX), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, Cancer Research Technology Limited (CRT) and The Institute of Cancer Research, London, have initiated a collaboration to discover and develop drug candidates targeting an undisclosed epigenetic target in a blood cancer with high unmet medical need.

The collaboration combines Astex's world-renowned fragment-based drug discovery platform and epigenetic* drug development experience with the expertise in blood cancer biology at The Institute of Cancer Research (ICR) and proven success in drug discovery at the Cancer Research UK Cancer Therapeutics Unit at the ICR.

Dysregulated epigenetic mechanisms are now understood to underlie a variety of cancer types, and have been successfully targeted by the first generation of epigenetic anticancer drugs**. In some cases, specific epigenetic mutational events can be linked to disease etiology, providing an opportunity to develop highly targeted personalised medicines and associated companion diagnostics that will ultimately improve survival and reduce side effects.

"We are delighted to be entering into this new collaboration with the ICR and CRT on a key epigenetics target," said Harren Jhoti, PhD, president of Astex Pharmaceuticals. "This new partnership builds on the highly successful collaboration which Astex entered into with the ICR and CRT in 2003 on another cancer target, PKB/Akt. That collaboration led to the discovery of two clinical candidates, the first of which, AZD5363, was taken into Phase I by our partner AstraZeneca in early 2011 and the second of which, AT13148, is being prepared to be taken into Phase 1 under our development partnership with Cancer Research UK. "

Professor Paul Workman, director of the Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research, said: "ICR scientists are pioneers at unravelling blood cancer drug targets, which others have considered challenging to drug effectively. We have a very strong track record of designing drugs to attack challenging biological targets and bringing them into clinical trial, and given Astex's complementary expertise, we are very excited about the potential of this collaboration."

Dr Phil L'Huillier, director of business management at CRT, said: "Putting in place this collaboration between the Cancer Research UK-funded drug discovery team at the ICR and Astex provides a powerful route to identify drug candidates for this promising new target.

"The deal will ensure that the research programme benefits from the necessary investment to progress the research to its full potential while building on the validation and assay development work that has been carried out at the ICR and funded by Cancer Research UK and others.

"We hope that this research will lead to the development of new drugs to ultimately improve survival for cancer patients."


'/>"/>
Contact: Jane Bunce
jane.bunce@icr.ac.uk
44-207-153-5106
Institute of Cancer Research
Source:Eurekalert

Related medicine news :

1. David H. Koch donates $10 million to Mount Sinais Jaffe Food Allergy Institute
2. Bascom Palmer Eye Institute announces breakthrough for degenerative vision disorder
3. The Ludwig Institute for Cancer Research announces launch of iTeos Therapeutics SA
4. A North American first at the Montreal Heart Institute
5. UC Santa Barbaras Kavli Institute receives 2 grants to explore interface of physics and biology
6. Data release from the Allen Institute for Brain Science expands online atlas offerings
7. Los Robles Hospital’s Annual Health Fair Attended by Khanna Institute
8. Patient Experience Regional Roundtables Announced by The Beryl Institute
9. Stanford Woods Institute for the Environment announces 2012 Environmental Venture Project awards
10. Aetna Institute Designates RSC New England Center of Excellence
11. To tackle health cares thorniest problems, 400 health researchers form new U-M-based institute
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... Asante, a nationally recognized ... have expanded their existing home health joint venture through an agreement, effective October ... a joint venture home health company with Asante, delivering clinically integrated care, for ...
(Date:10/12/2017)... ... October 12, 2017 , ... Dr. ... recently contributed a medical article to the newly revamped Cosmetic Town journal ... spotlights the hair transplant procedure known as Follicular Unit Extraction (FUE). ...
(Date:10/12/2017)... D.C. (PRWEB) , ... October 12, 2017 , ... Leading ... their peers in Washington, D.C., for the 49th Congress of the International Society ... ., Vice President of the Center for Cancer and Blood Disorders at ...
(Date:10/12/2017)... ... 12, 2017 , ... Women-owned and Grand Rapids-based workplace wellness ... in Wellness® by Best and Brightest. OnSite Wellness will be honored at the ... 7:30 a.m. to 2 p.m. at the Henry Autograph Collection Hotel, located at ...
(Date:10/12/2017)... ... October 12, 2017 , ... In the United States, ... In some states—like New York, New Jersey, Massachusetts, Texas, Virginia, Connecticut, and California—the ... have extremely low property-tax rates, which contributes to the relatively lower cost of ...
Breaking Medicine News(10 mins):
(Date:9/22/2017)... 2017  As the latest Obamacare repeal effort moves ... (R-LA) and Lindsey Graham (R-SC) medical ... device industry is in an odd place.  The industry ... excise tax on medical device sales passed along with ... patients, increased visits and hospital customers with the funding ...
(Date:9/19/2017)... ARBOR, Mich. , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical device ... precise destruction of targeted tissues, announced three leadership team developments today:   ... Stopek, PhD ... ... Veteran medical device executive ...
(Date:9/18/2017)... KALAMAZOO, Mich. , Sept. 18, 2017 ... , and OptiMed Specialty Pharmacy of Kalamazoo, ... offer a strategic hub service that expedites and streamlines ... personal spirometer, Spiro PD 2.0, and wellness management services.  ... is a medical device used to measure lung function ...
Breaking Medicine Technology: